Liana Moussatos

Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects

Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform

Kala Pharma Has 2 Material Milestones Upcoming In Q4

Wedbush Finally Steps Off The Sidelines, Bumps BioMarin To Outperform

Kala Pharma Has 2 Material Milestones Upcoming In Q4

Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion

Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey

Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion

Expect A Pair Of Drug Approvals From BioMarin In 2017; Stock Remains Pricey

Why miRagen Therapeutics Shares Could See 60% Upside By 2018

Analysts Split On How To Read Intercept Switching Clinical Trial Endpoints

Liana Moussatos Recent News

Your Guide To 2017's Emerging Pharmaceuticals Catalysts

'Steady Growth' For Relypsa's Veltassa Launch

Every Biotech Catalyst Wedbush Is Watching In 2016

Wedbush Hikes Relypsa Target To $86 On Edge Of U.S. Veltassa Launch

Wedbush Offers Probabilities For Upcoming Catalysts In Emerging Pharmas

EXCLUSIVE: Relypsa Being Evaluated By 3-4 Potential Acquirers; Sanofi Seen As 'Natural Buyer'

Analyst: No Catalyst For Big Move In XOMA, Could Be Traders Bottom Feeding Stock

Wedbush See 470% Upside At Xoma

Relypsa Plunges After Veltassa FDA Approval; Wedbush Says 'Misunderstanding' Creates Buying Opportunity

Wedbush Thinks Pacira Pharma Is Worth $106 On Exparel Sales

Wedbush Upbeat On Vitae Pharmaceuticals Despite Diabetes Results

Wedbush Sees Bidding War For Receptos

Wedbush: Regulus Therapeutics Will Quadruple In Price Within 12 Months

Analysts Positive On Intercept Pharmaceuticals After Earnings, Pipeline Update

Wedbush Securities Believes Financing Further Extends Cash Runway For Intercept Pharmaceuticals

Wedbush Securities Believes SH Data Bodes Well For Pacira Pharmaceuticals

Wedbush Expects Cash Runway To Last Through Anticipated Catalysts In 2015 For XOMA

XOMA Shares Spike Higher Following Wedbush Price Target Increase

Will Intercept Pharma Outperform? These Analysts Think So

Is $160 The Level To Watch At Receptos? Wedbush Thinks So

XOMA Corp Volatile Amid Differing Analyst Reports

Wedbush Securities Reacts To Regulus Therapeutics Inc Announcing ATHENA Natural History Study

Analysts Weigh In: Regado Future 'Unclear' As Shares Fall Below Cash Value